CdGAP is required for transforming growth factor Β- and Neu/ErbB-2-induced breast cancer cell motility and invasion

Oncogene

Volumn 30, Issue 9, 2011, Pages 1032-1045

  He, Y ^a   Northey, J J ^a,b   Primeau, M ^a   MacHado, R D ^c   Trembath, R ^c,d   Siegel, P M ^a,b   Lamarche Vane, N ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

breast cancer; cell migration and invasion; Rho GTPases; RhoGAPs; TGF

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; CDC42 GTPASE ACTIVATING PROTEIN; COLLAGEN TYPE 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PROTEIN CDC42; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EXPLANT; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLINE RICH PROTEIN DOMAIN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

ANIMALS; CADHERINS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GTPASE-ACTIVATING PROTEINS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM INVASIVENESS; NEUREGULIN-1; PHOSPHORYLATION; PROLINE-RICH PROTEIN DOMAINS; RECEPTOR, ERBB-2; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA;

EID: 79952281344     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.477     Document Type: Article

References (45)

1. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. (2000). Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchy-mal transition and cell migration. J Biol Chem 275: 36803-36810. (Pubitemid 32002090)
2. Barrios-Rodiles M, Brown KR, Ozdamar B, Bose R, Liu Z, Donovan RS et al. (2005). High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307: 1621-1625. (Pubitemid 40354744)
3. Broussard JA, Webb DJ, Kaverina I. (2008). Asymmetric focal adhesion disassembly in motile cells. Curr Opin Cell Biol 20: 85-90.
4. Bustelo XR, Sauzeau V, Berenjeno IM. (2007). GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessay 29: 356-370. (Pubitemid 46597867)
5. Carragher NO, Frame MC. (2004). Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol 14: 241-249. (Pubitemid 38591328)
6. Cerione RA, Zheng Y. (1996). The Dbl family of oncogenes. Curr Opin Cell Biol 8: 216-222. (Pubitemid 26109095)
7. Danek EI, Tcherkezian J, Meriane M, Triki I, Lamarche-Vane N. (2007). Glycogen synthase kinase-3 phosphorylates CdGAP at a consensus ERK1 regulatory site. J Biol Chem 282: 3624-3631. (Pubitemid 47084472)
8. Derynck R, Zhang YE. (2003). Smad-dependent and Smad-indepen-dent pathways in TGF-beta family signaling. Nature 425: 577-584. (Pubitemid 37280136)
9. Gomez del Pulgar T, Benitah SA, Valeron PF, Espina C, Lacal JC. (2005). Rho GTPase expression in tumorigenesis: evidence for a significant link. Bioessays 27: 602-613. (Pubitemid 40896091)
10. Gupta SK, Gallego C, Johnson GL. (1992). Mitogenic pathways regulated by G protein oncogenes. Mol Biol Cell 3: 123-128. (Pubitemid 23094258)
11. Huber MA, Kraut N, Beug H. (2005). Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558. (Pubitemid 41267170)
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. (2008). Cancer statistics, 2008. CA Cancer J Clin 58: 71-96. (Pubitemid 351521864)
13. Jenna S, Hussain NK, Danek EI, Triki I, Wasiak S, McPherson PS et al. (2002). The activity of the GTPase-activating protein CdGAP is regulated by the endocytic protein intersectin. J Biol Chem 277: 6366-6373. (Pubitemid 34968430)
14. Jiang W, Betson M, Mulloy R, Foster R, Levay M, Ligeti E et al. (2008). p190A RhoGAP is a glycogen synthase kinase-3-b substrate required for polarized cell migration. J Biol Chem 283: 20978-20988.
15. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. (2009). Rho GTPase function in tumorigenesis. Biochim Biophys Acta 1796: 91-98.
16. Kim TY, Vigil D, Der CJ, Juliano RL. (2009). Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev 28: 77-83.
17. Lalonde D, Grubinger M, Lamarche-Vane N, Turner CE. (2006). CdGAP associates with actopaxin to regulate integrin-dependent changes in cell morphology and motility. Curr Biol 16: 1-11.
18. Lamarche-Vane N, Hall A. (1998). CdGAP, a novel proline-rich GTPase-activating protein for Cdc42 and Rac. J Biol Chem 273: 29172-29177. (Pubitemid 28507617)
19. Miettinen PJ, Ebner R, Lopez AR, Derynck R. (1994). TGF-beta induced transdifferentiation of mammary epithelial cells to me-senchymal cells: involvement of type I receptors. J Cell Biol 127: 2021-2036.
20. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. (1988). Single-step inductionof mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105-115.
21. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE et al. (2003). Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol 23: 8691-8703. (Pubitemid 37433371)
22. Muraoka-Cook RS, Dumont N, Arteaga CL. (2005). Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 11: 937S-943S. (Pubitemid 40111109)
23. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM et al. (2006). Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 25: 3408-3423. (Pubitemid 43877044)
24. Nagaraj NS, Datta PK. (2010). Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 19: 77-91.
25. Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ et al. (2008). Signaling through ShcA is required for transforming growth factor B and Neu/Erb2-induced breast cancer cell motility and invasion. Mol Cell Biol 28: 3162-3176. (Pubitemid 351657082)
26. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. (2005). Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 307: 1603-1609. (Pubitemid 40354739)
27. Pardali E, ten Dijke P. (2009). Transforming growth factor-beta signaling and tumor angiogenesis. Front Biosci 14: 4848-4861.
28. Raftopoulou M, Hall A. (2004). Cell migration: Rho GTPases lead the way. Dev Biol 265: 23-32. (Pubitemid 38018819)
29. Siegel PM, Dankort DL, Hardy WR, Muller WJ. (1994). Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14: 7068-7077. (Pubitemid 24326370)
30. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. (2003). Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Natl Acad Sci USA 100: 8430-8435. (Pubitemid 36842562)
31. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapes and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182. (Pubitemid 17231334)
32. Southgate L, Machado RD, Snape KM, Primeau M, Dafou D, Ruddy DM. et al. Gain-of-Function Mutations of ARHGAP31, a Rho family GTPase regulator, cause Syndromic Cutis Aplasia and Limb Anomalies. N Engl J Med (submitted).
33. Tcherkezian J, Danek EI, Jenna S, Triki I, Lamarche-Vane N. (2005). Extracellular signal-regulated kinase 1 interacts with and phosphor-ylates CdGAP at an important regulatory site. Mol Cell Biol 25: 6314-6329. (Pubitemid 41023209)
34. Tcherkezian J, Lamarche-Vane N. (2007). Current knowledge of the large RhoGAP family of proteins. Biol Cell 99: 67-86. (Pubitemid 46242033)
35. Tcherkezian J, Triki I, Stenne R, Danek EI, Lamarche-Vane N. (2006). The human orthologue of CdGAP is a phosphoprotein and a GTPase-activating protein for Cdc42 and Rac1 but not RhoA. Biol Cell 98: 445-456. (Pubitemid 44203904)
36. Titus B, Schwartz MA, Theodorescu D. (2005). Rho proteins in cell migration and metastasis. Crit Rev Eukaryot Gene Expr 15: 103-114. (Pubitemid 41277406)
37. Tomar A, Lim ST, Lim Y, Schlaepfer DD. (2009). A FAK-p120RasGAP- p190RhoGAP complex regulates polarity in migrating cells. J Cell Sci 122: 1852-1862.
38. Tybulewicz VL, Henderson RB. (2009). Rho family GTPases and their regulators in lymphocytes. Nat Rev Immunol 9: 630-644.
39. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. (2007). Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 7: 389-397. (Pubitemid 46652484)
40. Van Aelst L, D'Souza-Schorey C. (1997). Rho GTPases and signaling networks. Genes Dev 11: 2295-2322. (Pubitemid 27408529)
41. Vega FM, Ridley AJ. (2008). Rho GTPases in cancer cell biology. FEBS Lett 582: 2093-2101.
42. Wang SE, Wu FY, Shin I, Qu S, Arteaga CL. (2005). Transforming growth factor {beta} (TGF-{beta})-Smad targ. Mol Cell Biol 25: 4703-4715.
43. Wong CM, Yam JW, Ching YP, Yau TO, Leung TH, Jin DY et al. (2005). Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 65: 8861-8868. (Pubitemid 41377375)
44. Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C et al. (2008). DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 22: 1439-1444. (Pubitemid 351793078)
45. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J et al. (2002). Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109: 1607-1615. (Pubitemid 34663523)